Evidence map›Paper›PMID 38239637›Full record

ArticleFrontiers in oncology2023

A germline

Zhuanghui Hao, Juan Li, Feng Gao, Weixiao Ren, Xiaomei Lu, Jinyi Feng, Chen Zhang, Sicheng Bian, Juan Xie, Ming Luo and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Novel germlineChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Zhuanghui HaoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Juan LiInstitute of Genetics, Changzhi Maternal and Child Health Hospital, Changzhi, China.
Feng GaoClinical Laboratory, The First Hospital of Shanxi Medical University, Taiyuan, China.
Weixiao RenInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xiaomei LuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jinyi FengInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Chen ZhangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Sicheng BianInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Juan XieInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ming LuoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jianmei ChangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wanfang YangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ruixia HouInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Daniel Muteb MuyeyInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jing XuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jiangxia CuiInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xiuhua ChenInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Hongwei WangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Shanxi Medical University · CNSecond Hospital of Shanxi Medical University · CNChangzhi Medical College · CNFirst Hospital of Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It has been discovered that Janus kinase 2 ( Methods: We designed a colony analysis of tumor cells obtained from this patient, and attempted to identify mutant genes using DNA from hair follicles. Mutation impairment prediction and conservative analysis were conducted to predict the mutation impairment and structure of Results: Three distinct tumor subclones, namely Conclusion: Our study revealed that the

Indexed as

CALR type1 mutationdistinct phenotypeessential thrombocythemiaJAK2 exon12 mutationmyeloproliferative neoplasms

Identifiers

PMID38239637
PMCPMC10794477
OpenAlexW4390584950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.